Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00718718 · ClinicalTrials.gov registry record · Phase 2
A Study of Effectiveness and Safety of CNTO 136 in Patients With Active Rheumatoid Arthritis Despite Methotrexate Therapy
A Phase 2 study, sponsored by Centocor.
- Completed
- Registry status
- Phase 2
- Development phase
- 187
- Enrollment target
NCT00718718 is a Phase 2 study that has completed, run by Centocor. The registered enrollment target is 187 participants.
The verdict
NCT00718718, a Phase 2 study, has completed, sponsored by Centocor.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 187 participants
- Enrollment target
Study Summary
The purpose of this study is to evaluate the effectiveness and safety of subcutaneous (under the skin) administration of anti-interleukin-6 monoclonal antibody (CNTO 136) in reducing signs and symptoms of participants with active rheumatoid arthritis (RA) with methotrexate (MTX) therapy.
Interventions
- DRUG Placebo
- DRUG Methotrexate
- DRUG CNTO 136 100 mg
- DRUG CNTO 136 50 mg
- DRUG CNTO 136 25 mg
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 187 participants |
| Start Date | 2008-08-11 |
| Est. Completion | 2011-03-03 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00718718
The ClinicalTrials.gov registry entry for NCT00718718 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 187 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Centocor, which has 33 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 5 interventions - of which Placebo is the first listed.
NCT00718718 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00718718 about?
NCT00718718 is a clinical study titled "A Study of Effectiveness and Safety of CNTO 136 in Patients With Active Rheumatoid Arthritis Despite Methotrexate Therapy". The purpose of this study is to evaluate the effectiveness and safety of subcutaneous (under the skin) administration of anti-interleukin-6 monoclonal antibody (CNTO 136) in reducing signs and symptoms of participants with active rheumatoid arthritis (RA) with methotrexate (MTX) therapy.
What is the current status of trial NCT00718718?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 187 participants. The study started on 2008-08-11. Estimated completion is 2011-03-03.
What interventions are being tested in trial NCT00718718?
The interventions under investigation include: Placebo (DRUG), Methotrexate (DRUG), CNTO 136 100 mg (DRUG), CNTO 136 50 mg (DRUG), CNTO 136 25 mg (DRUG).
Who is sponsoring clinical trial NCT00718718?
This trial is sponsored by Centocor, which has 33 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.